2026 Q2 -tulosraportti
11 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sitten · MuokattuNovo director defends himself after criticism When the Danish pharmaceutical giant Novo Nordisk recently delivered its latest financial report, it once again caused the stock price to fall. And that led CEO Mike Doustdar to declare that Novo needs to move at a "completely different pace". - It requires more work. It requires one to get up earlier and go to bed later, said the CEO at Novo Nordisk at an online press conference. Subsequently, DR has had two trade unions criticize the director's statements as 'unworthy' and 'a harsh signal' about the work culture. But the director apparently does not share that view himself. On LinkedIn, he rejects the criticism Saturday evening. - Despite the impressive title, I am far too small a cog to be able to change such a strong culture as Novo Nordisk's on my own. - Over the past year, I have also learned that when one is in the spotlight, one's words and actions will be interpreted and judged by both people who know one well and people who do not. It comes with the job, and I accept that, he writes in a comment to a post” https://www.linkedin.com/posts/morten-tind-abildlund-907b09146_there-has-been-a-lot-of-discussion-in-the-activity-7494356605363310592-0d3J
·7 t sittenNovo Nordisk is a big disappointment for me. Right now it stands at - 27000 kr. 😭😭Can one even get +27000 from a stock. Very difficult, I think. Fortunately, Microsoft has risen. The two hit me at one point - 60000 kr. 😂😂
·10 t sittenWhen is the dividend available in our account ?
·14 t sittenI bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordiskInsider-abe Jim Cramer reevaluates Novo Nordisk (NVO) as Wegovy pill adoption accelerates Syeda Seirut Javed Saturday, August 15, 2026 at 02:42 GMT+3 4 minutes read NVO -1.78% Shares in the Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced strong volatility after the latest quarterly results. In the August 12 Mad Money episode, Jim Cramer pointed out the gap between the company's strong performance and Wall Street's initial negative knee-jerk reaction. Cramer commented: "Okay, what happened to the shares of Novo Nordisk, the Danish pharmaceutical company, you know, as the inventor of Ozempic and Wegovy. Last week, they reported a beat and raise quarter, but the stock fell almost 6% that day the numbers were released. Since then, it has recovered most of the losses, but it was a surprising reaction. Hey, remember, Novo Nordisk helped invent the entire GLP-1 category, and their obesity and diabetes businesses are now printing money. In January, they launched a pill version of Wegovy. It has already been prescribed more than 5 million times, mostly to people who have never tried the injections. In the end, however, it's a turnaround story... but it still doesn't get much love from Wall Street." https://finance.yahoo.com/healthcare/articles/jim-cramer-reevaluates-novo-nordisk
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
11 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten · MuokattuNovo director defends himself after criticism When the Danish pharmaceutical giant Novo Nordisk recently delivered its latest financial report, it once again caused the stock price to fall. And that led CEO Mike Doustdar to declare that Novo needs to move at a "completely different pace". - It requires more work. It requires one to get up earlier and go to bed later, said the CEO at Novo Nordisk at an online press conference. Subsequently, DR has had two trade unions criticize the director's statements as 'unworthy' and 'a harsh signal' about the work culture. But the director apparently does not share that view himself. On LinkedIn, he rejects the criticism Saturday evening. - Despite the impressive title, I am far too small a cog to be able to change such a strong culture as Novo Nordisk's on my own. - Over the past year, I have also learned that when one is in the spotlight, one's words and actions will be interpreted and judged by both people who know one well and people who do not. It comes with the job, and I accept that, he writes in a comment to a post” https://www.linkedin.com/posts/morten-tind-abildlund-907b09146_there-has-been-a-lot-of-discussion-in-the-activity-7494356605363310592-0d3J
- ·7 t sittenNovo Nordisk is a big disappointment for me. Right now it stands at - 27000 kr. 😭😭Can one even get +27000 from a stock. Very difficult, I think. Fortunately, Microsoft has risen. The two hit me at one point - 60000 kr. 😂😂
- ·10 t sittenWhen is the dividend available in our account ?
- ·14 t sittenI bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordiskInsider-abe Jim Cramer reevaluates Novo Nordisk (NVO) as Wegovy pill adoption accelerates Syeda Seirut Javed Saturday, August 15, 2026 at 02:42 GMT+3 4 minutes read NVO -1.78% Shares in the Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced strong volatility after the latest quarterly results. In the August 12 Mad Money episode, Jim Cramer pointed out the gap between the company's strong performance and Wall Street's initial negative knee-jerk reaction. Cramer commented: "Okay, what happened to the shares of Novo Nordisk, the Danish pharmaceutical company, you know, as the inventor of Ozempic and Wegovy. Last week, they reported a beat and raise quarter, but the stock fell almost 6% that day the numbers were released. Since then, it has recovered most of the losses, but it was a surprising reaction. Hey, remember, Novo Nordisk helped invent the entire GLP-1 category, and their obesity and diabetes businesses are now printing money. In January, they launched a pill version of Wegovy. It has already been prescribed more than 5 million times, mostly to people who have never tried the injections. In the end, however, it's a turnaround story... but it still doesn't get much love from Wall Street." https://finance.yahoo.com/healthcare/articles/jim-cramer-reevaluates-novo-nordisk
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
11 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten · MuokattuNovo director defends himself after criticism When the Danish pharmaceutical giant Novo Nordisk recently delivered its latest financial report, it once again caused the stock price to fall. And that led CEO Mike Doustdar to declare that Novo needs to move at a "completely different pace". - It requires more work. It requires one to get up earlier and go to bed later, said the CEO at Novo Nordisk at an online press conference. Subsequently, DR has had two trade unions criticize the director's statements as 'unworthy' and 'a harsh signal' about the work culture. But the director apparently does not share that view himself. On LinkedIn, he rejects the criticism Saturday evening. - Despite the impressive title, I am far too small a cog to be able to change such a strong culture as Novo Nordisk's on my own. - Over the past year, I have also learned that when one is in the spotlight, one's words and actions will be interpreted and judged by both people who know one well and people who do not. It comes with the job, and I accept that, he writes in a comment to a post” https://www.linkedin.com/posts/morten-tind-abildlund-907b09146_there-has-been-a-lot-of-discussion-in-the-activity-7494356605363310592-0d3J
- ·7 t sittenNovo Nordisk is a big disappointment for me. Right now it stands at - 27000 kr. 😭😭Can one even get +27000 from a stock. Very difficult, I think. Fortunately, Microsoft has risen. The two hit me at one point - 60000 kr. 😂😂
- ·10 t sittenWhen is the dividend available in our account ?
- ·14 t sittenI bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordiskInsider-abe Jim Cramer reevaluates Novo Nordisk (NVO) as Wegovy pill adoption accelerates Syeda Seirut Javed Saturday, August 15, 2026 at 02:42 GMT+3 4 minutes read NVO -1.78% Shares in the Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced strong volatility after the latest quarterly results. In the August 12 Mad Money episode, Jim Cramer pointed out the gap between the company's strong performance and Wall Street's initial negative knee-jerk reaction. Cramer commented: "Okay, what happened to the shares of Novo Nordisk, the Danish pharmaceutical company, you know, as the inventor of Ozempic and Wegovy. Last week, they reported a beat and raise quarter, but the stock fell almost 6% that day the numbers were released. Since then, it has recovered most of the losses, but it was a surprising reaction. Hey, remember, Novo Nordisk helped invent the entire GLP-1 category, and their obesity and diabetes businesses are now printing money. In January, they launched a pill version of Wegovy. It has already been prescribed more than 5 million times, mostly to people who have never tried the injections. In the end, however, it's a turnaround story... but it still doesn't get much love from Wall Street." https://finance.yahoo.com/healthcare/articles/jim-cramer-reevaluates-novo-nordisk
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt